Clinical and Healthcare Cost Characteristics of Severe Asthma Patients with Long-Term Control on Omalizumab: A Comparative Analysis with Patients Who Switched to Other Biologics
Patients with nonsevere type-2 inflammation and a high BMI can achieve effective asthma control with OML, reducing treatment costs. Identifying this phenotype can improve the cost-effectiveness of biologic therapies for patients with severe asthma.
Authors
- Susumu Satô (ORCID: https://orcid.org/0000-0002-9626-1090)
- Satoru Terada (ORCID: https://orcid.org/0000-0003-1748-5502)
- Kenta Nishi (ORCID: https://orcid.org/0000-0003-1876-8117)
- Hisako Matsumoto (ORCID: https://orcid.org/0000-0002-8754-6318)
- Toyohiro Hirai (ORCID: https://orcid.org/0000-0002-7431-9044)
- Mariko Kogo
- Natsuko Nomura
- Hironobu Sunadome (ORCID: https://orcid.org/0000-0002-4617-2348)
- Tsuyoshi Oguma (ORCID: https://orcid.org/0000-0001-8929-5420)
- Tadao Nagasaki (ORCID: https://orcid.org/0000-0002-3231-7841)
- Chie Morimoto (ORCID: https://orcid.org/0000-0001-5610-1909)
- Yusuke Hayashi (ORCID: https://orcid.org/0000-0003-3890-7882)
Institutions
- Kyoto University (JP)
- Kindai University Hospital (JP)
- Kyoto City Hospital (JP)
- Kindai University (JP)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2025-09-01
- DOI
- https://doi.org/10.2147/jaa.s523832
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00